SENTIEN BIOTECHNOLOGIES
Sentien Biotechnologies is a privately-owned, clinical-stage company developing novel cell therapies that restore balance to the immune system and transform treatment options for patients with systemic inflammatory diseases. The company's innovative blood conditioning approach has been proven to significantly enhance exposure and extend therapeutic activity of Mesenchymal Stromal Cells (MSCs). By immobilizing MSCs in an extracorporeal device, their flagship SBI-101 product enables sustained, controlled dosage of secreted anti-inflammatory and regenerative properties that are unattainable by direct injection or intravenous infusion. Sentien Biotechnologies was established in 2008 and is headquartered in Lexington, Massachusetts, United States.
SENTIEN BIOTECHNOLOGIES
Industry:
Biotechnology Health Care Therapeutics
Founded:
2008-01-01
Address:
Lexington, Massachusetts, United States
Country:
United States
Website Url:
http://www.sentienbiotech.com
Total Employee:
1+
Status:
Active
Contact:
781-361-9031
Email Addresses:
[email protected]
Total Funding:
15.13 M USD
Technology used in webpage:
Google Apps For Business Gravity Forms 1and1
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Current Advisors List
Current Employees Featured
Founder
Investors List
Chiesi Ventures
Chiesi Ventures investment in Series A - Sentien Biotechnologies
BioInnovation
BioInnovation investment in Series A - Sentien Biotechnologies
Mass Medical Angels
Mass Medical Angels investment in Series A - Sentien Biotechnologies
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund investment in Series A - Sentien Biotechnologies
MBLVC
MBLVC investment in Series A - Sentien Biotechnologies
Key Employee Changes
| Date | New article |
|---|---|
| 2020-07-09 | Sentien Biotechnologies Names Dr. Allen R. Nissenson as Chief Medical Officer |
Official Site Inspections
http://www.sentienbiotech.com Semrush global rank: 3.54 M Semrush visits lastest month: 4.14 K
- Host name: 104.21.38.60
- IP address: 104.21.38.60
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
